# US 2021/0268066 A1 · Methods and kits for treating pain

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0268066 A1
- Document ID: US20210268066A1
- Status: Published application
- Kind: A1
- Application number: 17/317,333
- Filed: 2021-05-11
- Published: 2021-09-02
- Earliest claimed: 2017-05-12
- Assignees: Duke University
- Applicants: Duke University
- Inventors: Ru-Rong Ji; Gang Chen; Zilong Wang; Changyu Jiang; Kaiyuan Wang
- Web page: https://patentgrep.com/patent/US20210268066A1

## CPC

- A61K 38/1774: {Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)}
- A61B 5/4824: {Touch or pain perception evaluation (A61B5/4821 takes precedence)}
- A61B 5/4848: {Monitoring or testing the effects of treatment, e.g. of medication}
- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 38/1709: {from mammals}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- C07K 14/70532: {B7 molecules, e.g. CD80, CD86}
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- A61B 5/4833: {Assessment of subject's compliance to treatment}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/80: {Vaccine for a specifically defined cancer}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure provides methods and kits for treating pain. More particularly, the present disclosure relates to methods of using PD-L1/PD-1-associated compounds to treat pain and/or bone destruction from bone cancer, and associated kits. The present disclosure also provides methods to assess the efficacy of compounds to suppress PD-1-associated nociceptive neuron activity.

## Claims

### Claim 1

A method of treating a subject suffering from pain, the method comprising administering to the subject a therapeutically effective amount of a compound capable of suppressing PD-1-associated nociceptive neuron activity such that the pain is treated, wherein the compound comprises one or more of a small molecular activator of PD-1 and a SHP-1 phosphatase activator.

### Claim at position 2

2-3. (canceled)

### Claim 4 (depends on 1)

The method according to claim 1, wherein the compound is administered to the subject's dorsal root ganglia, skin, muscle, joint or cerebral spinal fluid (CSF).

### Claim 5 (depends on 1)

The method according to claim 1, further comprising administering to the subject a pain reliever simultaneously or serially.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the pain reliever is morphine.

### Claim 7

A method of determining the efficacy of PD-1-associated nociceptive neuron activity suppression in a subject, the method comprising:
a. administering to the subject a therapeutically effective amount of a compound capable of suppressing PD-1-associated nociceptive neuron activity, wherein the compound comprises one or more of a small molecular activator of PD-1 and a SHP-1 phosphatase activator; and
b. conducting one or more quantitative sensory test(s) on the subject, wherein the one or more quantitative sensory test(s) is administered immediately after administration of the compound, and at one or more time points after administration of the compound, wherein a rapid change in mechanical pain sensitivity after administration of the compound indicates target engagement and efficacy of the therapy.

### Claim 8

(canceled)

### Claim 9 (depends on 7)

The method according to claim 7, wherein the one or more time points after administration of said compound is 30 minutes, 45 minutes, 1 hour, 2 hours, 3 hours, 6 hours and/or 12 hours after administration of said compound.

### Claim at position 9

10-11. (canceled)

### Claim 13

A kit for the treatment of pain in a subject, the kit comprising:
a. a therapeutically effective amount of a compound capable of suppressing PD-1-associated nociceptive neuron activity, wherein the compound comprises one or more of a small molecular activator of PD-1 and a SHP-1 phosphatase activator;
b. an apparatus for administering said compound; and
c. instructions for use.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The method according to claim 1, wherein the subject is a human.

### Claim 16 (depends on 7)

The method according to claim 7, wherein the subject is a human.

### Claim 17 (depends on 13)

The kit according to claim 13, wherein the subject is a human.

### Claim 18 (depends on 1)

The method according to claim 1, further comprising administering to the subject a PD-L1 protein.

### Claim 19 (depends on 7)

The method according to claim 7, further comprising administering to the subject a PD-L1 protein.

### Claim 20 (depends on 13)

The kit according to claim 13, wherein the compound further comprises a PD-L1 protein.
